Trade Vir Biotechnology VIR

VirBiotechnology live chart

Mga Pangunahing Kaalaman sa Instrumento

Weekly Search
Weekly
Daily
Petsa Isarado Pagbabago Change (%) Buksan High Low

VirBiotechnology news

Mga pinakabagong balita

Ipakita nang marami
Frances Wang 2025 Jun 12, 16:00

Stellar (XLM) Price Analysis: Where could XLM go in the upcoming days?

Stocks
Frances Wang 2025 Jun 12, 16:00

Crypto News Today: Bitcoin Price Down 1.85% as US PPI Rises

Cryptocurrencies
Ghko B 2025 Jun 12, 16:00

Dogecoin Price Prediction: Could Dogecoin Price Surge to $0.95?

Cryptocurrencies
Tommy Yap 2025 Jun 12, 16:00

Morning Note: Middle East Conflict Shakes Markets as Oil Soars, While AI Sector Eyes Growth

Morning Note Oil NVDA Tech
Ghko B 2025 Jun 11, 16:00

Crypto Market Sentiment: Crypto Fear and Greed Index Today

Cryptocurrencies
Tommy Yap 2025 Jun 11, 16:00

Morning Note: Adobe’s AI Momentum Leads Market Moves with Gold and Fed in Focus

Morning Note Gold Commodities Stocks
Ghko B 2025 Jun 10, 16:00

BTC USD Price Prediction: How much will Bitcoin be worth in 2030?

Cryptocurrencies
Ghko B 2025 Jun 10, 16:00

Wells Fargo Stock Slides 1.32%: Is Wells Fargo stock a good buy now?

Stocks

Info

Spread

0.05

Spread (%)

0.9653 %

Leverage

1:10

Interes sa Magdamagang Pagbili

-0.0597 %

Interes sa Magdamagang Pagtinda

-0.0292 %

Currency

USD

Trading Hours

Oras ng Pagsasara

Biyernes

13:31 - 19:59

Lunes

13:31-19:59

Martes

13:31-19:59

Miyerkules

13:31-19:59

Huwebes

13:31-19:59

Analys och statistik

Buksan

---

Nakaraang Pagsara

---

52 Linggo Mataas/Mababa

--- – ---

Market Cap

725749504

Natitirang Pagbabahagi

138238000

Petsa ng Mga Kita (Susunod)

0000-00-00

Pambayad si dividend

Araw ng Pag-alis ng Karapatan sa Dividend

Inaasahang Taunang Rate ng Dividend

0

Inaasahang Taunang Dividend Yield

0

EPS

-4.09

Alamin ang Higit Pa Tungkol sa Instrumentong ito

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Mga kaugnay na instrumento

view_all_instruments

latest_education_articles

Ipakita nang marami
Trustpilot